Stanford Researchers cite BioPharm Laboratories High Purity Thrombin
February 10, 2022
More accolades for BioUtah member BioPharm Laboratories – another journal article from the Journal of Biological Chemistry cites the use of BioPharm’s High Purity Thrombin being used to cleave protein in their protein purification process. This time from researchers at Stanford University.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic trait that can cause hemolytic anemia. To date, over 150 non-synonymous mutations have been identified in G6PD, with pathogenic mutations clustering near the dimer and/or tetramer interface and the allosteric NADP+-binding site. BioPharm has identified a small molecule which activates G6PD variants by stabilizing the allosteric NADP+ and dimer complex, suggesting therapeutics that target these regions may improve structural defects.
Recent News
- Intermountain Health Announces New Children’s Health President and Expands Leadership Role for Hospital President to Build on Legacy of Pediatric Excellence
- Seek Labs Unveils BioSeeker™
- Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
- Purgo Scientific Appoints Veteran MedTech Leader as Chief Executive Officer
- Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
- Improving Women’s Health: MobileODT Joins Liger Medical
